nach oben

Die Urologie

Erschienen in:

28.06.2021 | Hodentumoren | Leitthema

Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen

verfasst von: Dr. med. Isabella M. Zraik, Dr. med. Yasmine Heß-Busch

Erschienen in: Die Urologie | Ausgabe 7/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zur Behandlung von Hodentumoren werden verschiedene Chemotherapien verwendet. Die häufigsten Therapieregime sind PEB (Cisplatin, Etoposid, Bleomycin), Carboplatin Monotherapie (AUC 7), PEI (Cisplatin, Etoposid, Ifosfamid), TIP (Cisplatin, Ifosfamid, Paclitaxel) und GOP (Gemcitabin, Oxaliplatin, Paclitaxel). Hiermit gehen verschiedene Akut- und Spättoxizitäten einher. Hierzu zählen allgemeine Nebenwirkungen wie Anämie, Neutropenie, Übelkeit, Erbrechen, Durchfälle, Mukositis oder auch Paravasate sowie spezielle Toxizitäten wie Ototoxizität, Nephrotoxizität, pulmonale Toxizität, Neurotoxizität oder das Raynaud-Syndrom. Da in der Regel junge Männer betroffen sind, sind gerade auch die möglichen Langzeitfolgen wie Hypogonadismus, Infertilität oder das metabolische Syndrom sehr relevant. Dementsprechend ist ein adäquates Management der möglichen Nebenwirkungen und Langzeitfolgen im Rahmen des Einsatzes von Chemotherapien essentiell.

Aapro M, Saad F (2012) Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. Ther Adv Urol 4:85–10 PubMedPubMedCentralCrossRef

Abu Zaid M, Dinh PC, Monahan PO (2019) Adverse health outcomes in relationship to hypogonadism after chemotherapy: a multicenter study of testicular cancer survivors. J Natl Compr Canc Netw 17(5):459–468 PubMedPubMedCentralCrossRef

Adams SC, DeLorey DS, Davenport et al (2018) Effects of high-intensity interval training on fatigue and qualityof life in testicular cancer survivors. Br J Cancer 118:1313–1321 PubMedPubMedCentralCrossRef

Adoue D et al (1984) Bleomycin and Raynaud’s phenomenon. Ann Intern Med 100:770 PubMedCrossRef

Alkhateeb AA, Connor JR (2013) The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta 1836:245–254 PubMed

Auerbach M, Silberstein PT, Webb RT et al (2010) Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85:655–663 PubMedCrossRef

Bandak M et al (2017) A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild Leydig cell insufficiency (Einstein-intervention). Bmc Cancer 17:461 PubMedPubMedCentralCrossRef

Boer H, Proost JH, Nuver J et al (2015) Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Ann Oncol 26:2305–2310 PubMedPubMedCentralCrossRef

Bogefors C et al (2017) Hypogonadism in testicular cancer patients is associated with risk factors of cardiovascular disease and the metabolic syndrome. Andrology 5:711 PubMedCrossRef

10.

Brydøy M, Oldenburg J, Klepp O et al (2009) Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 101:1682–1695 PubMedPubMedCentralCrossRef

11.

Cella D, Kallich J, Mcdermott A et al (2004) The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 15:979–986 PubMedCrossRef

12.

Chovanec M, Zaid AM, Hanna N et al (2017) Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol 28:2670–2679 PubMedPubMedCentralCrossRef

13.

Daugaard G, Skoneczna I, Aass N et al (2011) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 22:1054–1061 PubMedCrossRef

14.

De Haas EC, Altena R, Boezen HM et al (2013) Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 24:749–755 PubMedCrossRef

15.

Dodd MJ, Larson PJ, Dibble SL et al (1996) Randomized clinical trial of chlorhexidine versus placebo for prevention of oral mucositis in patients receiving chemotherapy. Oncol Nurs Forum 23:921–927 PubMed

16.

Dodd MJ, Miaskowski C, Greenspan D et al (2003) Radiation-induced mucositis: a randomized clinical trial of micronized sucralfate versus salt & soda mouthwashes. Cancer Invest 21:21–33 PubMedCrossRef

17.

Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S (2018) EAU-Leitlinie Männlicher Hypogonadismus. J Reproduktionsmed Endokrinol_Online 15(2):71–88

18.

Dolan ME, El Charif O, Wheeler HE et al (2017) Clinical and genome-wide analysis of cisplatin-induced peripheral neuropathy in survivors of adult-onset cancer. Clin Cancer Res 23:5757–5768 PubMedPubMedCentralCrossRef

19.

Einhorn LH, Rapoport B, Navari RM et al (2017) 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 25:303–308 PubMedCrossRef

20.

Fallon MT, Storey DJ, Krishan A et al (2015) Cancer treatment-related neuropathic pain: proof of concept study with menthol—a TRPM8 agonist. Support Care Cancer 23:2769–2777 PubMedPubMedCentralCrossRef

21.

Fankhauser CD et al (2020) A risk-benefit analysis of prophylactic anticoagulation for patients with metastatic germ cell tumours undergoing first-line chemotherapy. Eur Urol. https://doi.org/10.1016/j.euf.2020.09.017 CrossRefPubMedPubMedCentral

22.

Feldman DR, Schaffer WL, Steingart RM (2012) Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw 10:537–544 PubMedCrossRef

23.

Flechtner HH et al (2016) Quality-of-life analysis of the German prospective multicentre trial of single-cycle adjuvant BEP versus retroperitoneal lymph node dissection in clinical stage I Nonseminomatous germ cell tumours. Eur Urol 69:518 PubMedCrossRef

24.

Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, Storm H, Hall P, Holowaty E, Andersen A, Joensuu H, Andersson M, Kaijser M, Gospodarowicz M, Cohen R, Pukkala E, Travis LB (2007) Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99(7):533–544 PubMedCrossRef

25.

Fung C, Fossa SD, Milano MT et al (2013) Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study. J Clin Oncol 31:3807–3814 PubMedPubMedCentralCrossRef

26.

Fung C, Fossa SD, Milano MT, Sahasrabudhe DM et al (2015) Cardiovascular disease mortality after chemotherapy or surgery for testicular nonseminoma: a population based study. J Clin Oncol 33:3105–3115 PubMedPubMedCentralCrossRef

27.

Green DM, Liu W, Kutteh WH et al (2014) Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol 15:1215–1223 PubMedPubMedCentralCrossRef

28.

Haugnes HS, Aass N, Fossa SD et al (2007) Components of the metabolic syndrome in long term survivors of testicular cancer. Ann Oncol 18:241–248 PubMedCrossRef

29.

Haugnes HS, Aass N, Fossa SD et al (2009) Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 27:2779–2786 PubMedCrossRef

30.

Haugnes HS, Wethal T, Aass N et al (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 28:4649–4657 PubMedCrossRef

31.

Haugnes HS, Stenklev NC, Brydøy M et al (2018) Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Acta Oncol 57:1075–1083 PubMedCrossRef

32.

Hjelle LV, Bremnes RM, Gundersen POM et al (2016) Associations between long-term serum platinum and neurotoxicity and ototoxicity, endocrine gonadal function, and cardiovascular disease in testicular cancer survivors. Urol Oncol 34:487.e413–487.e420 CrossRef

33.

Howard R et al (2008) Risk of leukemia among survivors of testicular cancer: a population based study of 42,722 patients. Ann Epidemiol 18:416 PubMedPubMedCentralCrossRef

34.

Huddart RA, Norman A, Shahidi M et al (2003) Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 21:1513–1523 PubMedCrossRef

35.

Hwang MS, Lee HY, Choi TY et al (2020) A systematic review and meta-analysis of the efficacy of acupuncture and electroacupuncture against chemotherapy-induced peripheral neuropathy. Medicine 99:e19837 PubMedPubMedCentralCrossRef

36.

Kwan EM et al (2017) Impact of Granulocyte-colony stimulating factor on Bleomycin induced pneumonitis in chemotherapy-treated germ cell tumors. Clin Genitourin Cancer. https://doi.org/10.1016/j.clgc.2017.08.012 CrossRefPubMed

37.

Lampe H, Horwich A, Norman A et al (1997) Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 15:239–245 PubMedCrossRef

38.

Lauritsen J et al (2016) Pulmonary function in patients with germ cell cancer treated with Bleomycin, Etoposide, and Cisplatin. J Clin Oncol 34:1492 PubMedCrossRef

39.

Leenstra JL, Miller RC, Qin R et al (2014) Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [Alliance]). J Clin Oncol 32:1571–1577 PubMedPubMedCentralCrossRef

40.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) (2017) Supportive Therapie bei onkologischen PatientInnen

41.

Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) (2019) S3-Leitlinie Diagnostik, Therapie und Nachsorge der Keimzelltumoren des Hodens

42.

Lorusso D, Bria E, Costantini A et al (2016) Patients’ perception of chemotherapy side effects: expectations, doctor-patient communication and impact on quality of life—an Italian survey. Eur J Cancer Care. https://doi.org/10.1111/ecc.12618 CrossRef

43.

Ludwig H, Müldür E, Endler G et al (2013) Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24:1886–1892 PubMedPubMedCentralCrossRef

44.

Mcguire DB, Fulton JS, Park J et al (2013) Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21:3165–3177 PubMedCrossRef

45.

Meinardi MT, Gietema JA, van der Graaf WT et al (2000) Cardiovascular morbidity in long term survivors of metastatic testicular cancer. J Clin Oncol 18:1725–1732 PubMedCrossRef

46.

Mhaskar R, Wao H, Miladinovic B et al (2016) The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009624.pub2 CrossRefPubMedPubMedCentral

47.

Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21:1655–1663 PubMedCrossRef

48.

Necchi A, Miceli R, Oualla K et al (2017) Effect of bleomycin administration on the development of pulmonary toxicity in patients with metastatic germ cell tumors receiving first-line chemotherapy: a meta-analysis of randomized studies. Clin Genitourin Cancer 15:213–220.e5 PubMedCrossRef

49.

Nichols CR et al (1993) Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 85:36 PubMedCrossRef

50.

O’Sullivan JM et al (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 14:91 PubMedCrossRef

51.

Ohlsson C, Wallaschofski H, Lunetta KL et al (2011) Genetic determinants of serum testosterone concentrations in men. PLoS Genet 7:e1002313 PubMedPubMedCentralCrossRef

52.

Pedrazzoli P, Farris A, Del Prete S et al (2008) Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 26:1619–1625 PubMedCrossRef

53.

Piketty AC et al (2005) The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface area. Br J Cancer 93:909 PubMedPubMedCentralCrossRef

54.

Pluschnig U, Haslik W, Bayer G et al (2015) Outcome of chemotherapy extravasation in a large patient series using a standardised management protocol. Support Care Cancer 23:1741–1748 PubMedCrossRef

55.

Poniatowska G et al (2020) What is the damage? Testicular germ cell tumour survivors deficient in testosterone at risk of metabolic syndrome and a need for medical intervention. Med Oncol 37:82–91 PubMedCrossRef

56.

Rao RD, Michalak JC, Sloan JA et al (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110–2118 PubMedCrossRef

57.

Raphael MJ, Logheed WX et al (2020) A population-based study of pulmonary monitoring and toxicity for patients with testicular cancer treated with bleomycin. Curr Oncol 27(6):291–298 PubMedPubMedCentralCrossRef

58.

Robinson AG et al (2020) Venous thromboembolism during chemotherapy for testicular cancer: a population-based study. Clin Oncol 32(10):e188–e193. https://doi.org/10.1016/j.clon.2020.03.013 CrossRef

59.

Seng S, Liu Z, Chiu SK et al (2012) Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and metaanalysis. J Clin Oncol 30:4416–4426 PubMedCrossRef

60.

Seto BG, Kim M, Wolinsky L et al (1985) Oral mucositis in patients undergoing bone marrow transplantation. Oral Surg Oral Med Oral Pathol 60:493–497 PubMedCrossRef

61.

Smith AB et al (2016) The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. J Cancer Surviv 10:223 PubMedCrossRef

62.

Smith EM, Pang H, Cirrincione C et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359–1367 PubMedPubMedCentralCrossRef

63.

Sprauten M, Darrah TH, Peterson DR et al (2012) Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol 30:300–307 PubMedCrossRef

64.

Streckmann F, Zopf EM, Lehmann HC et al (2014) Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 44:1289–1304 PubMedCrossRef

65.

Terbuch A, Posch F, Partl R et al (2018) Risk stratification for febrile neutropenia in patients with testicular germ cell tumors. Cancer Med 7:508–514 PubMedPubMedCentralCrossRef

66.

Thorsen L et al (2017) Thromboembolic events after high-intensity training during cisplatin-based chemotherapy for testicular cancer. J Clin Oncol 35:4551 CrossRef

67.

Travis LB, Fossa SD, Schonfeld SJ et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365 PubMedCrossRef

68.

Vehling S et al (2016) Anxiety and depression in long-term testicular germ cell tumor survivors. Gen Hosp Psychiatry 38:21 PubMedCrossRef

69.

Watson RA, De La Peña H, Tsakok MT et al (2018) Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. Br J Cancer 119:1044–1051 PubMedPubMedCentralCrossRef

70.

Willemse PM, Burggraaf J, Hamdy NAT et al (2013) Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer 109:60–67 PubMedPubMedCentralCrossRef

71.

Yeap BB (2009) Testosterone and ill-health in aging men. Nat Clin Pract Endocrinol Metab 5:113–121 PubMedCrossRef

72.

Cerchietti LC, Navigante AH, Körte MW et al (2003) Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain 105:265–273 PubMedCrossRef

73.

Fosså SD, Kaye SB, Mead GM et al (1998) Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 16:716–724 PubMedCrossRef

74.

Lalla RV, Bowen J, Barasch A et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–1461 PubMedCrossRef

Titel: Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen
verfasst von: Dr. med. Isabella M. Zraik
Dr. med. Yasmine Heß-Busch
Publikationsdatum: 28.06.2021
Verlag: Springer Medizin
Schlagwörter: Hodentumoren
Chemotherapie
Diarrhoe
Anämien
Diarrhoe
Übelkeit
Erbrechen
Hodentumoren
Neutropenie
Erschienen in: Die Urologie / Ausgabe 7/2021
Print ISSN: 2731-7064
Elektronische ISSN: 2731-7072
DOI: https://doi.org/10.1007/s00120-021-01569-7

Neu im Fachgebiet Onkologie

20.09.2023 | Mammakarzinom | Nachrichten

Impuls - Die Nachhaltigkeitsinitiative von Springer Medizin

Springer Medizin

Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen

Zusammenfassung

Neu im Fachgebiet Onkologie

Beeinträchtigt kontralateraler Brustkrebs die Überlebenschancen?

Tumortherapiefelder verlängern Leben bei NSCLC um drei Monate

Krebsbedingter Herzmuskelschwund: häufig und prognostisch ungünstig

NALIRIFOX verlängert Leben bei Pankreas-Ca. um zwei Monate

Update Onkologie

Impuls - Die Nachhaltigkeitsinitiative von Springer Medizin

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2021

Hodentumor und Peniskarzinom – Überleben mit Lebensqualität

Entscheidungshilfen beim Peniskarzinom: Konventionelles vs. molekulares Grading

Urologie Kolumne

Termine

Wirken Opioide unterschiedlich bei Mann und Frau?

AUO

Neu im Fachgebiet Onkologie

Beeinträchtigt kontralateraler Brustkrebs die Überlebenschancen?

Tumortherapiefelder verlängern Leben bei NSCLC um drei Monate

Krebsbedingter Herzmuskelschwund: häufig und prognostisch ungünstig

NALIRIFOX verlängert Leben bei Pankreas-Ca. um zwei Monate

Update Onkologie